Lakefront shares break their 250-session high and gain 4.5%

Nine-month net profit of €13.9 million driven by financial income

The group reports a net profit of €13.9 million for the first nine months of 2026, compared with a loss of €461.3 million a year earlier, according to its accounts published on November 11. This return to profit stems from financial income: €156.1 million in net financial income offset an operating loss of €148.4 million, which was reduced by 68% year on year.

Revenue fell 88% to €26.1 million, following the end of revenue linked to the agreement with Gilead.

The company targets year-end cash of between €2.0 billion and €2.05 billion and announces a second share buyback programme of €50 million. The first one, launched in August for the same amount, was about 59% executed by mid-October, i.e. €30 million repurchased.

In this release, the company also indicated that gamgertamig should enter registrational studies in autoimmune diseases in 2027.

Shares rise to €30.20 and gain 28% over three months

At €31.14, the stock broke through its 250-session high of €30.20, which has now become a support level. The share price sits 20% above its 200-day moving average, while the RSI, at 73, signals an overbought configuration.

Over three months, the stock has gained nearly 28%, compared with just over 4.5% over the week.

The next round-number level above is €32, with no prior technical resistance. The company will attend the Jefferies healthcare conference in London, where it will hold a fireside chat broadcast live, and will present a poster at the ASH congress, from December 12 to 15, on 33 patients with autoimmune cytopenias.